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Abstract: CMX001, a lipophilic nucleotide analog formed by covalently linking 
3-(hexdecyloxy)propan-1-ol to cidofovir (CDV), is being developed as a treatment for 
smallpox. CMX001 has dramatically increased potency versus CDV against all dsDNA 
viruses and, in contrast to CDV, is orally available and has shown no evidence of 
nephrotoxicity in healthy volunteers or severely ill transplant patients to date. Although 
smallpox has been eliminated from the environment, treatments are urgently being sought 
due to the risk of smallpox being used as a bioterrorism agent and for monkeypox virus, a 
zoonotic disease of Africa, and adverse reactions to smallpox virus vaccinations. In the 
absence of human cases of smallpox, new treatments must be tested for efficacy in animal 
models. Here we first review and discuss the rabbitpox virus (RPV) infection of New 
Zealand White rabbits as a model for smallpox to test the efficacy of CMX001 as a 
prophylactic and early disease antiviral. Our results should also be applicable to 
monkeypox virus infections and for treatment of adverse reactions to smallpox vaccination.  
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1. Introduction 
Although variola virus—the causative agent of human smallpox—has been eliminated from the 
natural environment, a human threat from weaponized variola virus remains [1–3]. Studies of variola 
virus antiviral compounds must therefore rely on testing in small animal models in order to evaluate 
potential efficacy [4]. In this study, we have used New Zealand White rabbits intradermally infected 
with rabbitpox virus strain Utrecht (RPV) as a model for smallpox and for human cases of monkeypox 
virus. Briefly, the characteristics that make RPV extremely attractive as a surrogate of variola and 
monkeypox viruses include: genetic similarity to both variola and monkeypox viruses, similarity of the 
pathophysiologic course of disease, low dose of virus to create lethal disease, correlation of viral 
burden with disease progression, and potential to model lesional disease. RPV virus, which causes a 
severe and lethal disease in rabbits, was first identified in the 1940s following an outbreak in a 
laboratory rabbit colony in Utrecht, Netherlands [5,6]. RPV and variola virus belong to the genus 
Orthopoxvirus, a group of viruses which share serological cross reactivity, genomic structure, virion 
morphology, and replication strategy [7–10]. Orthopoxviruses share similar pathogenesis in susceptible 
hosts, although some orthopoxviruses, such as variola virus, are very host restricted [11–14]. Interaction 
between the virus and host immune responses are thought to underlie the host range [15]. RPV is most 
closely related to vaccinia virus and is usually categorized as a subspecies of vaccinia (VV) [16], a 
classification substantiated by comparison of genomic sequences, which show an overall sequence 
similarity of 95% at the amino acid level [17]. RPV has enhanced pathogenicity for rabbits compared 
with VV and can be naturally transmitted in confined populations of rabbits, resulting in rapid spread 
and high mortality [18]. Transmission occurs via naturally generated aerosols in a manner similar to 
smallpox [18–20]. The ability of RPV to be easily spread by aerosol to uninfected rabbits and the 
overall course of disease closely parallels variola infections of human populations [21]. 
Intradermal inoculation of RPV in rabbits is a useful and relevant route of infection to model 
smallpox or monkeypox because a known inoculum volume can be delivered precisely and the course 
of disease is virtually indistinguishable from aerosol mediated rabbit to rabbit infection [19,22,23]. 
While the disease progression of intradermal and aerosol infections are clinically similar, it is 
important to note several differences between the two routes of infection, each offering specific key 
animal model advantages for human smallpox. First, the aerosol route of infection requires twice as 
much virus required to reach the LD50 when compared to intradermally infected animals, i.e., (20 pfu 
for aerosol [22,23] vs. 10 pfu for intradermal). The disease symptoms requiring euthanasia in both 
routes is respiratory distress, however this occurs 1–2 days sooner in aerosol infected animals than in 
intradermally infected rabbits, most likely due to differences in the primary site of infection (RPV 
intradermally inoculated must first replicate at the flank, spread to the lungs and cause pathology while 
RPV introduced via the aerosol route is instilled directly into the lung and does not need not to spread 
to cause respiratory distress). RPV intradermally inoculated into rabbits at very low doses (100 pfu) 
causes a systemic disease, extensive viremia, the development of secondary lesions, subsequent severe Viruses 2011, 3                  
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respiratory disease and death by nine days post infection. Thus, RPV infection of rabbits is a highly 
sensitive model for orthopoxvirus disease as well as spread and can be used to evaluate efficacy of 
poxvirus vaccines and antivirals. 
CMX001 is a lipophilic nucleotide analog formed by covalently linking 3-(hexdecyloxy)propan-1-ol 
to cidofovir (CDV). Cidofovir (marketed as Vistide
®), an antiviral drug approved for the treatment of 
CMV-retinitis [24,25], is an alternative substrate inhibitor of the DNA polymerases encoded by 
orthopoxviruses, and has shown activity in lethal models of poxvirus infection using mice and 
monkeys [26–30]. Although CDV is the only antiviral drug currently available for use in the event of a 
smallpox outbreak, its utility in an attack would be limited since it must be administered by slow 
intravenous infusion and has the potential for significant nephrotoxicity [31,32]. In an effort to address 
the need for an orally available antiviral drug for human poxvirus infections, a lipid conjugate of CDV 
was synthesized by covalently coupling CDV to hexadecylpropanediol, the resulting compound is 
referred to as CMX001 here forth. The conjugate was designed to resemble a natural phospholipid and 
utilize natural uptake pathways to achieve oral availability, high uptake in target cells and overall 
improved Absorption, Distribution, Metabolism, Excretion (ADME) profiles [33].  
In addition to the overall genetic similarity among orthopoxviruses, including variola and 
monkeypox viruses, the virally encoded DNA polymerase, which is the target of antiviral action for the 
active metabolite of CMX001, shows 97.9% amino acid identity and 99.2% strong similarity between 
RPV and a consensus of 48 variola virus isolates [34]. In vitro studies have shown that CMX001 is 
active against both RPV and variola viruses with IC50 values of 0.5 µM and 0.1 µM, respectively [35]. 
CMX001 has been previously shown to be effective in vivo using murine models of orthopoxvirus 
infections [36–38]. 
We have used the intradermal inoculation RPV model to evaluate the efficacy of CMX001 as a 
potential prophylactic treatment for orthopoxvirus infection [19]. In this communication, our results 
demonstrate that CMX001 is effective in preventing mortality and reducing morbidity when 
administered prior to virus exposure and early in infection as compared to untreated animals. 
2. Results and Discussion 
2.1. The Infection of Rabbits by Rabbitpox Virus: Model Review 
The standardization of the rabbit/RPV model has been previously published [19] by our laboratory 
and the timing of both clinical symptoms and euthanasia criteria appearance are shown in Figure 1. 
The model is reviewed and summarized here to highlight the features important to evaluating antiviral 
compounds. Only the features of smallpox and rabbitpox virus infections are compared but 
monkeypox virus infections share similar properties. This model, which uses New Zealand   
White (NZW) rabbits infected with 100–1000 pfu of RPV (administered bilaterally) by intradermal 
injection, if untreated, is almost uniformly lethal (Figure 2A). There are few differences between 100 
and 1000 pfu observed in RPV infected nine week old NZW rabbits most likely due to the fact the 
doses are 10× and 100×, respectively, the LD50 dose. The appearance of swelling at the primary site of 
infection occurs 12–24 hours earlier in animals infected with 1000 pfu as compared to 100 pfu, but the 
overall symptomology follows the same time line. The disease begins with a local reaction at the site Viruses 2011, 3                  
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of virus introduction visualized as a raised red swelling within 1–2 days post infection (dpi). The lesion 
continues to grow in both diameter and thickness over the next 6–8 days. Necrosis at the primary site 
of infection develops by 3 to 4 dpi. The lesion reaches maximal diameter of 8–10 cm, with a thickness 
of 1–2 cm and encompasses the entire flank of the rabbit at the time of euthanasia. The progression of 
the primary lesion over time is shown in Figure 3. 
Figure 1. Timeline of disease in 8–10 week old New Zealand White rabbits infected 
intradermally with 1000 pfu rabbitpox virus (RPV). Symptoms in boxes above the timeline 
represent clinical measurements that contribute to euthanasia guidelines. Clinical 
symptoms are located below the timeline. Reproduced with permission from American 
Society for Microbiology [19]. 
 
 
The first clinical signs of systemic disease are the presentation of a fever (Figure 2C) and failure to 
gain weight (Figure 2B) that begins at 3–4 dpi. Weight loss continued until the animals are euthanized. 
A failure to gain weight for young, growing animals is a sign of disease and weight loss is a symptom 
of severe disease. A fever in the rabbits is a body temperature of 39.5°C or higher as measured by the 
subcutaneous temperature transponders. RPV infected animals exhibited fevers generally from 3 dpi to 
euthanasia when the body temperatures of infected animals could on occasion drop drastically. The 
severity of disease is quantified using the clinical score (Figure 2D); RPV infected animals exhibited 
severe disease with an average maximum clinical score of 22.4 points out of a possible 33 points. 
Secondary lesions were initially observed in the ears and generally appear 3–5 dpi, 12–24 hours 
after the first sign of a fever is observed. The lesions first appeared in the ears as small red spots 
typically found at the bend of a blood vessel and are easily visualized by backlighting the ears. The 
progression of these small red spots to pustular lesions on the ears is shown in Figure 3. It is important 
to note that the secondary lesions found in the ears, unlike those observed with vaccinia virus, are 
small because the rabbits succumb to disease before the lesions fully develop. Secondary lesions were 
also found on the nose, eyelids, in and around the mouth, genitals and as a rash across the body of 
the rabbit. 
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Figure 2. Disease in rabbits lethally infected with RPV compared to age/weight matched 
mock infected rabbits. (A) Survival; (B) Average weight change from weight at time of 
infection for each group. Negative values represent weight loss. (C) Average body 
temperatures over time. Temperatures over 39.5 °C are considered a fever. (D) Average 
clinical score over time. Error bars represent SEM. Reproduced with permission from 
American Society for Microbiology [19]. 
 
 
Animals infected with RPV were ultimately euthanized due to respiratory distress characterized by 
open mouth breathing, a decrease in respiration rate to below 40 breaths per minute or severe lung 
sounds. The respiratory symptoms began at approximately 5 dpi and progress to euthanasia criteria 
levels by 7–9 dpi. At the time of euthanasia it was typical to observe profuse mucopurulent discharge 
from the nostrils and severe discharge from the eyes. 
Upon necropsy, virus was recovered from all tissues collected including the skin (both lesion and 
non-lesion containing normal appearing skin), lungs, liver, spleen, gonad and blood. The LD50 of RPV 
in nine week old 3–4 lb NZW rabbits is approximately 10 pfu (data not shown). 
RPV in rabbits shares many of the same pathophysiologic features of variola in humans. The 
replication and spread of RPV and variola within the host are believed to be very similar [15]. In both 
RPV and smallpox, there is an incubation period during which the virus replicates locally and spreads 
to key tissues, most notably the lymphoid cells of the reticuloendothelial system. Replication in these 
cells produces a secondary viremia which results in disseminated infection affecting a wide range of 
organs. Both RPV and smallpox produce fever, malaise, and the typical pox lesions on the skin. In 
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addition, both RPV and smallpox exhibit high mortality rates [15,20]. Monkeypox in humans results in 
a very similar disease although lethality is lower. 
Figure 3. Ears and primary inoculation site of RPV infected NZW rabbits over time. 
Rabbits were infected as described in Figure 2. The top row of photographs shows the 
progression of secondary lesions in the ears of RPV infected rabbits. Arrows note the site 
of secondary lesions. The bottom row of photographs shows the progression of the primary 
lesions over time. Bars represent 1 cm. 
 
 
The occurrence of lesions in the RPV model is an important parallel with smallpox infections. 
Human data with smallpox show a positive relationship between the extent of lesions and the   
mortality rate. For ordinary-type variola major infections, increased severity of lesions—discrete, 
semi-confluent, and confluent—was correlated with increased death rates of 9.3, 37, and 62%, 
respectively [15,39].  
The degree of involvement of the respiratory tract is perhaps the most significant difference 
between RPV and smallpox. In RPV, the respiratory tract is a key site of viral replication whether  
the animals are infected via the respiratory tract, intradermally, or by animal to animal transmission 
[19,20]. Rabbits infected with RPV exhibit obvious signs of respiratory distress including profuse 
mucopurulent discharge from the nostrils and slow, labored, frequently open-mouth   
breathing [19]. Respiratory distress is the most frequent trigger for euthanasia in RPV [19]. In 
smallpox, respiratory distress is usually not cited as the cause of death; however, there is clearly 
respiratory tract involvement. For example, the earliest lesions in smallpox cases are those occurring in 
the oropharyngeal cavities which are thought to be the result of the secondary viremia [15]. 
Furthermore, in his review of literature, Martin [40] noted viral pneumonia and airway compromise as 
key contributing causes of smallpox-related death. Therefore, the difference in respiratory tract 
involvement between RPV and smallpox may be one of degree rather than an absolute difference. 
Another key difference between RPV and smallpox is the time course of the disease. In smallpox, 
deaths occur approximately 22 to 28 days after infection, whereas in RPV, deaths (euthanasia) in Viruses 2011, 3                  
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vehicle treated intradermally infected animals occur between six and 10 days post infection. Therefore, 
the window of opportunity for effective antiviral therapy is expected to be larger in smallpox compared 
to RPV. 
It is also informative to consider the cause of death in smallpox versus RPV. The cause of death in 
smallpox has been debated over the years, but one current view is that uncontrolled inflammatory 
responses resulting from a deregulated cytokine cascade contribute to a shock-like syndrome, 
hypotension, and failure of key organs [41,42]. As noted above, the most frequent trigger for 
euthanasia in RPV is respiratory distress. However in studies where rabbits were allowed to die 
naturally of the infection, extreme hypotension and elevated potassium levels were cited as the most 
consistent physiological changes [43,44]. In speculating on the cause of the hypotension, Boulter et al. 
comment that “it is more probable that the endogenous mechanisms activated in general inflammation 
... are implicated.” Therefore, the underlying disease processes leading to death may be very similar 
between smallpox and RPV. 
2.2. Efficacy of Prophylactic administration of CMX001 in Preventing RPV Induced Disease 
The initial study performed was to evaluate and determine the minimum dose of CMX001 required 
to protect otherwise lethally infected rabbits from RPV disease. Animals received either 100 or   
1000 pfu RPV. For this report, these animals were grouped together based upon dosage of CMX001 
received. There was no difference between the groups that received 100 or 1000 pfu RPV in severity 
of disease presentation for the initial experiments; therefore, for all future studies 100 pfu RPV was 
used. It is noteworthy that although the clinical presentation was virtually identical, animals receiving 
the higher dose of RPV did exhibit clinical symptoms 12–24 hours earlier than those animals receiving 
100 pfu RPV. CMX001 was administered prior to infection as a pre-exposure prophylactic treatment. 
Protective effects of CMX001 were evaluated at doses of 1, 5, 10 and 20 mg/kg. Animals that received 
dosages of 1, 5 or 10 mg/kg received CMX001 twice a day (BID), morning and late afternoon, for five 
days beginning one day prior to infection. The group of animals receiving 20 mg/kg were administered 
CMX001 once a day (QD) in the morning for five days beginning one day prior to infection. All tested 
doses of CMX001 were protective against lethal RPV disease (Table 1) while vehicle treated animals 
were euthanized at 6.6 ± 0.16 dpi due to respiratory distress.  
Table 1. Minimum dosage of orally administered CMX001 that provides protection to 
RPV disease when treatment is begun one day prior to infection with RPV. QD designates 
drug administered once a day; BID designates drug administered twice a day at 
concentrations indicated in the table. 
CMX001 
Dose (mg/kg)  
Dosing 
Frequency  
Day of Dosing 
(dpi)  
Mean Time to 
Death ± SEM  
Survival at  
Day 14PI  
1 BID    −1 to 3   NA   4/4 (100%)*  
5 BID    −1 to 3   NA   4/4 (100%)*  
10 BID    −1 to 3   NA   6/6 (100%)**  
20   QD   −1 to 3   NA   6/6 (100%)**  
Vehicle   BID  −1 to 3   6.6 ± 0.16  0/10 (0%)  
*p = 0.0099; **p = 0.0012 as compared to vehicle. Viruses 2011, 3                  
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Although all the animals that received CMX001 were protected from lethal RPV disease there was 
a difference in clinical symptoms that was dependent on the dose of CMX001 received. Animals 
treated with 5 or 10 mg/kg BID or 20 mg/kg QD exhibited few clinical symptoms over the course  
of the experiment. All three treatment groups exhibited a positive weight change, indicating a nearly 
constant weight gain, with no significant differences between groups (Figure 4A). Animals that   
received 1 mg/kg of CMX001 exhibited a weight loss profile similar to that of the vehicle treated 
animals (Figure 4A).  
Animals treated with 1 mg/kg CMX001 also exhibited a body temperature increase similar to that in 
both severity and duration compared to the vehicle treated animals (Figure 4B). The 5 mg/kg treated 
group exhibited a mild temperature spike with a maximal temperature of 40.2 °C as compared   
to 41.2 °C for vehicle treated animals. The temperature spike was three days later than that observed 
with either the 1 mg/kg or the vehicle treated animals lasting for approximately the same duration of 
four days (Figure 4B).  
While the animals exhibited both weight loss and fevers, the overall health of the animals treated 
with 1 mg/kg, as measured by the more comprehensive overall clinical score, was markedly lower  
than that of the vehicle treated animals (Figure 4C). The overall level of disease as measured by 
clinical scores demonstrated that animals treated with 5, 10 or 20 mg/kg CMX001 exhibited only  
mild disease (Figure 4C).  
Figure 4. Clinical observations for evaluation of minimum dosage of CMX001 to provide 
protection from RPV disease. Animals were dosed at concentrations and schedules as 
outlined in Table 1. (A) Average weight change from weight at day of infection. Negative 
values indicated weight loss. (B) Average body temperatures. (C) Average clinical scores. 
(D) Pictures of primary lesions from representative animals at 7 dpi. Bars represent 1 cm. 
Black circles denote site of intradermal inoculation. 
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The primary lesions of animals treated with 1 mg/kg CMX001 did become swollen and necrotic but 
did not become as large or edematous as those of the vehicle treated animals (Figure 4D compare first 
and last photographs). Animals treated with 1 mg/kg CMX001 exhibited numerous secondary lesions 
on the ears, nose and mouths (data not shown). The primary lesions of animals treated with 5 mg/kg 
were small in diameter and exhibited necrosis early in the experiment that rapidly resolved to a scab. 
Animals treated with 10 or 20 mg/kg exhibited no noteworthy primary lesion with little to no swelling 
early and no necrosis (Figure 4D). These animals also exhibited few if any secondary lesions on the 
ears, nose or mouth as compared to vehicle or 1 mg/kg CMX001 treated animals (data not shown). 
The clinical score is used as a more comprehensive and inclusive measure of overall health of the 
study animals and as such can be used to gauge the severity of disease observed throughout the course 
of the experiment. A concern with any antiviral treatment is the shifting or simply delaying the disease 
course corresponding to withdrawal of the antiviral agent. Therefore, to assess the level of protection 
CMX001 provided to treated animals, the maximum clinical score and maximum weight loss for each 
animal were compared. 
When the maximum clinical score for a group over the course of the experiment is used as a 
measure of maximal illness observed during the course of the experiment it is observed that treatment 
with CMX001 provides a statistically significant reduction in the disease severity for all treatment 
groups (Figure 5A). While the maximum weight loss for each treatment group is not statistically 
significant when compared to the maximum weight loss of the vehicle treated animals, a dose 
dependent trend was observed (Figure 5B). Animals treated with 1 mg/kg CMX001 did not follow this 
trend, however, exhibited a larger weight loss than vehicle treated animals. This was attributed to a 
combination of multiple secondary lesions in the mouth causing difficulty for the animals to eat food 
and their prolonged survival as compared to vehicle animals. 
Figure 5. Disease severity measurements for evaluation of minimum dosage of CMX001 
to provide protection from RPV disease. Animals were dosed at concentrations and 
schedules as outlined in Table 1. (A) Average maximum clinical scores for each animal per 
group over the course of the experiment. (B) Average maximum percent weight loss from 
weight at day 0 for each animal per group over the course of the experiment. 
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Upon necropsy at euthanasia (14 dpi), no virus was detected in any of the sampled internal organs 
in any of the treated animals. Virus was only detected at the primary site of infection. In contrast, 
vehicle treated animals had virus detected in all tissues sampled as well as at the primary site of 
infection (data not shown). 
2.3. CMX001 Dose Response against RPV Infection 
Based upon results from the experiments to evaluate the efficacy of CMX001 when administered as 
a pre-exposure prophylactic, the next evaluation of CMX001 was to determine whether treatment once 
a day beginning just after exposure during the asymptomatic period would also be effective against 
RPV induced disease. We examined the ability of CMX001 to reduce morbidity and prevent mortality 
at different doses when treatment was initiated at Day 1 post infection where animals received only a 
single daily dose of CMX001. The doses used were 2, 5, 10, and 20 mg/kg once a day for five days 
beginning at 1 dpi. As shown in Table 2, no rabbits treated with CMX001 were euthanized for severe 
RPV disease during the 14-day study period while animals receiving vehicle required euthanasia   
at 7 ± 1 dpi.  
Table 2. Evaluation of minimal dosage of CMX001 that provides protection when 
administered once a day (QD) when dosing is begun 1 day post infection for five days. 
CMX001 Dose 
(mg/kg)  
Dosing 
Frequency  
Day of Dosing 
(dpi)  
Mean Time to 
Death ± SEM  
Survival at  
Day 14PI  
2  QD   1 to 5   NA   4/4 (100%)*  
5  QD   1 to 5   NA   4/4 (100%)*  
10   QD   1 to 5   NA   4/4 (100%)*  
20   QD   1 to 5   NA   2/2 (100%)**  
Vehicle   QD  1 to 5   7±1  0/2 (0%)  
*p = 0.06; **p = 0.33 as compared to vehicle. 
 
Although all rabbits dosed with CMX001 survived, a dose dependent response in disease severity 
was observed between the treatment groups. The degree of weight loss and recovery from RPV disease 
measured by the return of weight gain was CMX001 dose dependent. Animals that received 2 mg/kg 
exhibited mild weight loss from 4 to 10 dpi while the weight loss exhibited by 5 mg/kg treated animals 
was similar in rate to the 2 mg/kg treatment group but returned to a positive weight gain by 8 dpi. 
Rabbits that received 10 or 20 mg/kg CMX001 showed few symptoms including no substantial weight 
loss with a general positive trend in weight change (Figure 6A). The maximum weight loss for each 
group was also evaluated (Figure 7B) and again demonstrated an inverse relationship between the dose 
of CMX001 and weight loss in which the higher doses of CMX001 demonstrated virtually no weight 
loss from baseline weight. 
All treatment groups exhibited temperature spikes from 3 to 8 dpi with similar profiles, however 
there was a dose response trend observed in which the groups treated with lower concentrations of 
drug exhibited higher maximal temperature spikes (Figure 6B). The overall disease as measured by 
clinical scores showed the same trend observed with weight loss and body temperature in which there 
was a dose response where the higher doses of CMX001 led to a lower clinical score indicating fewer Viruses 2011, 3                  
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symptoms of RPV induced disease (Figure 6C). The primary lesions for all treated groups were similar 
as observed in the first study in which the higher the dosage of CMX001 the less swelling, edema and 
necrosis present (Figure 6D). Animals treated with 20 mg/kg had virtually no sign of a primary lesion 
by 5 dpi while animals treated with 5 or 10 mg/kg exhibited a small slightly swollen area with a central 
scab. Animals treated with 2 mg/kg CMX001 exhibited large primary lesions with necrosis that 
progressed to scabbing with the overall size of the lesions being larger in diameter from the other 
treatment groups. The presence of secondary lesions also inversely corresponded to the dose of 
CMX001 received in which animals that received 20 mg/kg CMX001 had no secondary lesions while 
those that received 2mg/kg had numerous secondary lesions. 
Figure 6. Clinical observations for evaluation of minimum dose of CMX001 required for 
protection from RPV when treatment is begun 1 day post infection. Animals were dosed at 
concentrations and schedules as outlined in Table 2. (A) Average weight change for each 
group. (B) Average body temperatures for each group. (C) Average clinical scores for each 
group. Error bars represent SEM. (D) Representative photos of primary lesions for 
treatment groups at 5 dpi. 
 
 
Again, using the maximum clinical score and weight loss as indications of maximal illness it was 
observed that treatment with CMX001 provides a reduction in the disease severity for all treatment 
groups (Figure 7A). While the maximum weight loss for each treatment group is not statistically 
significant when compared to the −3.31% ± 0.79 weight loss maximum for vehicle treated animals, 
there is a dose dependent trend observed (Figure 7B). While the weight loss for animals treated   
with 2 and 5 mg/kg CMX001 is larger than that observed with vehicle treated animals, this may again 
be attributed to number of secondary lesions in the mouth and prolonged survival as compared to 
vehicle animals. 
We found that the CMX001 given once a day from Day 1 to Day 5 PI protects rabbits from lethal 
disease caused by RPV virus. These animals fared much better than the previous QD group that began 
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treatment at Day -1 instead of Day 1, since the current drug dosing plan afforded the rabbits two extra 
days of drug protection during the actual viral infection. 
Figure 7. Disease severity measurements for evaluation of minimum dose of CMX001 
required for protection from RPV when treatment is begun 1 day post infection. Animals 
were dosed at concentrations and schedules as outlined in Table 2. (A) Average maximum 
clinical scores for each animal per group over the course of the experiment. (B) Average 
maximum percent weight loss from weight at day 0 for each animal per group over the 
course of the experiment. 
 
 
2.4. Comparison of CMX001 Treatment Time of Initiation 
Given that CMX001 at relatively low doses was protective against RPV induced morbidity and 
mortality, we examined the impact of a delay in dosing on the development of severe disease. 
Therefore, we examined the ability of CMX001 to reduce morbidity and prevent mortality when 
administered at 5 mg/kg BID for five days when treatment was initiated at −1, 0, 1, 2, 3, 4, 5, or 6 dpi 
for groups of four female rabbits. The treatment groups have been separated based upon initiation of 
treatment into pre (−1 to 2 dpi) and post symptomatic (3 to 6 dpi) for comparison of all data. The 
systemic RPV induced disease (including fever and secondary lesion formation) is not observable  
until 3–4 dpi and therefore is the rationale for this separation. 
All vehicle treated control rabbits required euthanasia on Day 7 post infection due to respiratory 
failure and severe RPV induced disease. In contrast, all rabbits treated with CMX001 survived for the 
14-day study period when treatment was initiated at 4 dpi or earlier (Table 3). When treatment   
was initiated at 5 dpi, three of four rabbits survived and when treatment was initiated on 6 dpi one of 
four rabbits survived. 
In groups in which CMX001 treatment was initiated at the pre symptomatic stage (−1 to 2 dpi), 
animals had few disease symptoms including fever, weight loss and average clinical score profiles over 
the course of the experiment (Figure 8A–C). All animals in the pre symptomatic treatment groups did 
exhibit a body temperature above 39.5 °C between 4 and 9 dpi and slight weight loss that recovered  
by 12 dpi for all groups. The primary lesions (Figure 8G top row) were increasing larger as the delay 
in dosing increased, however were small compared to the vehicle treated animals and all were healed 
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by 14 dpi. There were few secondary lesions observed in groups where treatment was initiated   
at −1 to 1 dpi, with more secondary lesions present on animals in which treatment was initiated at 2 
dpi. No animals exhibited severe respiratory disease during the course of the experiment. 
Table 3. Evaluation of survival when dosage with CMX001 is delayed up to 6 days post 
infection. Animals were dosed twice a day (BID) for 5 days beginning at day indicated in 
the days of dosing column of the table. All animals received 5mg/kg CMX0001. 
CMX001 
Dose (mg/kg)  
Frequency of 
Dosing  
Day of Dosing 
(dpi)  
Mean Time to 
Death ± SEM  
Survival at  
Day 14PI  
5 BID  −1 to 3  NA   4/4 (100%)  
5   BID   0 to 4   NA   4/4 (100%)  
5   BID   1 to 5   NA   4/4 (100%)  
5   BID   2 to 6   NA   4/4 (100%) 
5   BID   3 to 7   NA   4/4 (100%)  
5   BID   4 to 8   NA   4/4 (100%)  
5   BID   5 to 9   9 ± 0  3/4 (75%) 
5   BID   6 to 10   9.3 ± 0.9  1/4 (25%) 
Vehicle   BID   Vehicle   7 ± 0  0/4 (0%)  
 
Post symptomatic stage treated groups of animals (treatment initiated at 3 to 6 dpi) exhibited more 
pronounced RPV induced disease than in the pre symptomatic treatment groups. Animals that received 
CMX001 treatment beginning at 3 dpi exhibited disease nearly indistinguishable from that of animals 
receiving CMX001 beginning at 2 dpi, however the primary lesion was larger in size and there were 
more secondary lesions, as would be expected from a 1 day delay in initiating treatment. While all the 
animals survived when treatment was begun at 4 dpi, all animals showed numerous secondary lesions 
and fairly substantial weight loss with a larger primary lesion exhibiting necrosis. The three of four 
animals that survived from the group in which treatment was initiated on 5 dpi had numerous 
secondary lesions, weight loss and moderate respiratory disease. When treatment was initiated at 6 dpi 
all animals exhibited severe RPV disease-related symptoms characterized by large, necrotic primary 
lesion, numerous secondary lesions, weight loss and respiratory disease (Figure 8D–F). It is important 
to note that at 5–6 dpi in the course of a normal, untreated RPV infection, the animals are 
demonstrating severe, advanced disease with fevers, weight loss, numerous secondary lesions and 
respiratory disease. 
Maximum clinical score and weight loss were again used as indications of maximal illness over for 
all groups tested. It was observed that in groups in which all animals survived (0 to 3 dpi) with few 
clinical symptoms the maximum average clinical scores were significantly lower than that of the 
vehicle treated animals (Figure 9A). Animals that began treatment 1 day prior to infection had a lower 
maximum clinical score than that of vehicle treated animals, it was, however, not significant. There 
was an advantage noted to having treatment for five days in the presence of virus infection when 
comparing the group in which treatment was initiated on −1 dpi as compared to those that began 
treatment 0 to 2 dpi. As treatment was initiated later in infection, as expected the disease severity 
increased, showing a time of treatment dependence in the maximum disease severity observed. In Viruses 2011, 3                  
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groups in which not all the animals survived (5 and 6 dpi treatment groups), there was little difference 
in the maximum clinical score as compared to vehicle treated animals. 
Figure 8. Clinical observations for evaluation of survival when dosage with CMX001 is 
delayed up to six days post infection. Animals were dosed at concentrations and schedules 
as outlined in Table 3. (A) Average weight change from weight at day of infection. 
Negative values indicated weight loss (B) Average body temperatures. (C) Average 
clinical scores. The higher the number, the more severe the disease presentation.   
(D) Pictures of primary lesions from representative animals at 6 or 7 dpi. Bars represent  
1 cm. Black circles denote site of intradermal inoculation. 
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As observed with the maximum clinical score, the maximum average weight loss also exhibited a 
time of treatment initiation dependence on the maximal weight loss. When treatment was begun by 
2  dpi animals exhibited little weight loss, while when treatment was begun between 3 and 6 dpi 
animals exhibited weight loss in excess of the vehicle treated group (Figure 9B). This is likely due to 
the fact that the vehicle treated animals are euthanized due to severe respiratory disease before 
significant weight loss can occur. 
Figure 9. Disease severity measurements for evaluation of survival when dosage with 
CMX001 is delayed up to six days post infection. Animals were dosed at concentrations 
and schedules as outlined in Table 3. (A) Average of maximum clinical scores for each 
animal per group over the course of the experiment. (B) Average of maximum percent 
weight loss from weight at day 0 for each animal per group over the course of   
the experiment.  
 
 
We found that the initiation of CMX001 treatment can be delayed to 4 dpi for protection against 
RPV induced morbidity and mortality. There was a statistically significant protection against RPV 
induced disease when treatment was delayed up to 5 dpi. This allows for a large window for treatment 
opportunity from pre- to post-exposure and treatment of systemic disease with significant protection 
and reduction in RPV disease. 
3. Experimental Section 
3.1. Cell and Virus Growth 
CV-1 cells were maintained in Minimum Essential Media (MEM) with Earle’s Salts (Gibco, New 
York, USA) supplemented with 2 mM glutamine (Media Tech, Virginia, USA), 50 U/mL penicillin  
G and 50 µg/mL streptomycin (Media Tech), 1 mM sodium pyruvate (Media Tech), and   
0.1 mM nonessential amino acids (Media Tech), and 10% v/v FBS (Gibco). 
Rabbitpox virus (RPV) was obtained from ATCC and virus stocks used in these experiments   
were ≤5 passages from the original stock and have maintained virulence as evidenced by an LD50 in  
9-week old NZW rabbits of approximately 10 pfu by the intradermal route. All viruses for animal 
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infections were pad purified over 36% sucrose using standard methods and resuspended in PBS. 
Viruses were titered on CV-1 cells using standard methods. [45,46]  
3.2. Housing of Animals 
For intradermally infected rabbits, 8 week (3–4lb) old NZW rabbits were obtained from Myrtle’s 
Rabbitry (Thompson Station, TN) and housed in standard in stainless steel solid back and side cages at 
20 °C and 12 h light/12 h dark regime. All animals obtained a unique ear tattoo number in the left ear 
prior to arrival at the study site. Animals were allowed to acclimate to their surroundings for 5–10 days 
prior to RPV infection. Food and water were available to the animals ad libitum. Rabbits received 
apples, alfalfa cubes, or fresh greens daily for enrichment. 
All animal procedures were approved by the University of Florida Institutional Animal Care and 
Use Committee. 
3.3. Animal Infections 
Intradermal infection was performed by bilateral shaving of both thighs of the rabbit, sterilizing  
with an isopropanol wipe followed by intradermal injection of 100 or 1000 pfu RPV using a 27 gauge 
needle [19]. The injection site was then traced using a black permanent marker to note the site   
of infection. 
3.4. Monitoring of Animals 
Rabbit were microchipped at the time of infection to transmit body temperature and unique 
identification number (Bio Medic Data Systems, Seaford, DE). Rabbits underwent a complete physical 
daily. Rabbits were euthanized upon the onset of severe respiratory distress (labored, extremely slow 
or open mouth breathing) or weight loss of greater than 15% of initial body weight. 
Clinical scores for each rabbit each day were generated by assigning numerical values of 0 to 4 for 
all clinical measurements obtained during the course of the evaluation of each rabbit. These 
measurements included: weight change (loss, no change or gain), body temperature (low, within 
normal limits, fever), respiration rate (normal, depressed), heart rate (normal, decreased), intake and 
output, overall attitude and posture, presence of secondary lesions (number of secondary lesions and 
number of sites present) and primary site of infection condition (degree of reaction). These scores are 
used as a measure of disease severity, where the higher the number the more severe the disease. 
Weight change was calculated as the percent change from weight on the day of infection with RPV. 
All statistical analysis was performed using an unpaired t test for each group measurement as 
compared to vehicle treatment groups. 
All animal procedures and euthanasia were carried out according to the University of Florida 
IACUC guidelines. 
3.5. CMX001 Dosing of Animals 
Animals were trained for 4–5 days prior to the initiation of the study to readily accept the 10% 
sucrose solution used to deliver CMX001 (HDP-CDV). The 10% sucrose training solution, vehicle Viruses 2011, 3                  
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solution and CMX001 was administered orally using a 1 mL disposable syringe with the end dipped in 
granulated sugar and fed orally to the animals. The total volume of liquid the animals received was 
approximately 1.0 mL. Dry powdered CMX001 (Chimerix Inc, North Carolina, USA) was dissolved in 
10% sucrose in water with food coloring to the required concentration. Vehicle treated animals 
received 10% sucrose solution only. In a previous pharmacokinetic study all rabbits treated with 
CMX001 for 7 days at doses up to 25 mg/kg/day survived to the scheduled termination. In this special 
issue there is a review on the development of CMX001 for further toxicological data. 
4. Conclusions 
We reviewed the salient features of the rabbitpox virus infection of rabbits as a model system for 
systemic orthopoxvirus disease, key features of human smallpox, monkeypox and certain adverse 
complications arising from vaccination. We then used this system to evaluate the ability of CMX001, 
either administered prophylactically or after exposure but prior to the onset of symptoms to prevent 
death and clinical symptoms. Our findings suggest that CMX001 administered either prophylactically 
or soon after infection prior to the onset of symptoms is very effective in preventing death and 
lessening clinical symptoms of rabbitpox infection. It is important to note that CMX001 has a 
mechanism of action different from that of ST-246 [47], another effective smallpox antiviral drug 
under development. Having multiple antiviral drugs with different mechanisms of action decreases the 
risk of developing resistance. We believe that the powerful antiviral effects of CMX001 suggest that 
the drug would be a very effective treatment for human smallpox or other orthopoxvirus infections. 
Every concentration of CMX001 from 1 mg/kg to 20 mg/kg tested gave significant protection when 
treatment was began prior to or within 24 hours of infection independent of whether the drug was 
administered once or twice a day. 
Treatment could be delayed up to 4 dpi when administered twice a day at 5 mg/kg for five days and 
give complete protection from RPV morbidity and mortality. Administration of CMX001 at 5 dpi 
provided 75% survival in animals evaluated. These results suggest that a strict schedule of dosing is 
not critical to maintain antiviral effects in vivo. It is important to note, perhaps not surprisingly, that 
even though virtually any treatment prevents death, that depending on dose and delay in onset of 
treatment, significant clinical symptoms can occur. The severity of symptoms correlates with lower 
doses and delays in beginning treatment. The delay in treatment post exposure will be examined 
further in light of results in the final study presented in this paper in the accompanying paper dealing 
with post symptomatic treatment with CMX001 of RPV infected rabbits. 
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